EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plant‐produced SARS ‐ CoV ‐2 antibody engineered towards enhanced potency and in vivo efficacy

Steven W de Taeye iD, Loïc Faye, Bertrand Morel, Angela I Schriek, Jeffrey C Umotoy, Meng Yuan, Natalia A Kuzmina, Hannah L Turner, Xueyong Zhu, Clemens Grünwald-Gruber, Meliawati Poniman, Judith A Burger und 16 weitere

Plant Biotechnology Journal · 2025

DOI: 10.1111/pbi.14458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Plant Biotechnology Journal, 2025. Verfasst von Steven W de Taeye und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam UMC location University of Amsterdam, Ams…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Antibodies, Viral, Antibodies, Monoclonal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: amfAR, The Foundation for AIDS Research, Aidsfonds, Bill & Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prevention of severe COVID‐19 disease by SARS‐CoV‐2 in high‐risk patients, such as immuno‐compromised individuals, can be achieved by administration of antibody prophylaxis, but producing antibodies can be costly. Plant expression platforms allow substantial lower production costs compared to traditional bio‐manufacturing platforms depending on mammalian cells in bioreactors. In this study, we describe the expression, production and purification of the originally human COVA2‐15 antibody in plants. Our plant‐produced mAbs demonstrated comparable neutralizing activity with COVA2‐15 produced in mammalian cells. Furthermore, they exhibited similar capacity to prevent SARS‐CoV‐2 infection in a hamster model. To further enhance these biosimilars, we performed three glyco‐ and protein engineering techniques. First, to increase antibody half‐life, we introduced YTE‐mutation in the Fc tail; second, optimization of N ‐linked glycosylation by the addition of a C‐terminal ER‐retention motif (HDEL), and finally; production of mAb in plant production lines lacking β‐1,2‐xylosyltransferase and α‐1,3‐fucosyltransferase activities (FX‐KO). These engineered biosimilars exhibited optimized glycosylation, enhanced phagocytosis and NK cell activation capacity compared to conventional plant‐produced S15 and M15 biosimilars, in some cases outperforming mammalian cell produced COVA2‐15. These engineered antibodies hold great potential for enhancing in vivo efficacy of mAb treatment against COVID‐19 and provide a platform for the development of antibodies against other emerging viruses in a cost‐effective manner.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19Antibodies, ViralAntibodies, MonoclonalProtein EngineeringAnimalsHumansCricetinaeAntibodies, NeutralizingGlycosylationNicotianaPlants, Genetically ModifiedSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

SARS‐CoV‐2antibodyeffector functionengineeringglycosylationstructure

Substanzen

Antibodies, ViralAntibodies, MonoclonalAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam institute for Immunology and Infectious Diseases, Infectious Diseases, Amsterdam, The Netherlands.
  • ANGANY Innovation, 1 voie de l'innovation, Pharmaparc II, Val de Reuil, France.
  • Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
  • Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
  • Galveston National Laboratory, Galveston, Texas, USA.

ORCID-Profile: Steven W de Taeye, Véronique Gomord

Förderung

  • amfAR, The Foundation for AIDS Research
  • Aidsfonds
  • Bill & Melinda Gates Foundation
  • Bill and Melinda Gates Foundation

Zitieren

APA

de Taeye, S. W., Faye, L., Morel, B., Schriek, A. I., Umotoy, J. C., Yuan, M., Kuzmina, N. A., Turner, H. L., Zhu, X., Grünwald-Gruber, C., Poniman, M., Burger, J. A., Caniels, T. G., Fitchette, A. C., Desgagnés, R., Stordeur, V., Mirande, L., Beauverger, G., de Bree, G., …, & Gomord, V. (2025). Plant‐produced SARS ‐ CoV ‐2 antibody engineered towards enhanced potency and in vivo efficacy. Plant Biotechnology Journal. https://doi.org/10.1111/pbi.14458

Vancouver

de Taeye SW, Faye L, Morel B, Schriek AI, Umotoy JC, Yuan M, et al. Plant‐produced SARS ‐ CoV ‐2 antibody engineered towards enhanced potency and in vivo efficacy. Plant Biotechnology Journal. 2025. doi:10.1111/pbi.14458

BibTeX
@article{deTaeye2025,
  author = {de Taeye, Steven W and Faye, Loïc and Morel, Bertrand and Schriek, Angela I and Umotoy, Jeffrey C and Yuan, Meng and Kuzmina, Natalia A and Turner, Hannah L and Zhu, Xueyong and Grünwald-Gruber, Clemens and Poniman, Meliawati and Burger, Judith A and Caniels, Tom G and Fitchette, Anne-Catherine and Desgagnés, Réjean and Stordeur, Virginie and Mirande, Lucie and Beauverger, Guillaume and de Bree, Godelieve and Ozorowski, Gabriel and Ward, Andrew B and Wilson, Ian A and Bukreyev, Alexander and Sanders, Rogier W and Vezina, Louis-Philippe and Beaumont, Tim and van Gils, Marit J and Gomord, Véronique},
  title = {Plant‐produced SARS ‐ CoV ‐2 antibody engineered towards enhanced potency and in vivo efficacy},
  journal = {Plant Biotechnology Journal},
  year = {2025},
  doi = {10.1111/pbi.14458}
}
Kostenlos starten →